Correspondence and offprint requests to: Gheun-Ho Kim; E-mail:
Nephrol Dial Transplant. 2010 May;25(5):1520-4. doi: 10.1093/ndt/gfp657. Epub 2009 Dec 9.
Cyclophosphamide is an alkylating agent and was traditionally known to potentiate the renal action of vasopressin. Although low-dose intravenous pulse cyclophosphamide therapy is being used extensively in the treatment of malignant and rheumatological diseases, there have been only a few case reports of cyclophosphamide-induced hyponatraemia.
Clinical data were retrospectively analysed from 84 patients (42 lupus nephritis; 42 non-Hodgkin's lymphoma; a total of 112 treatment episodes) admitted for intravenous pulse cyclophosphamide (500-750 mg/m(2)) therapy. In all patients, half-isotonic saline was used for prophylactic hydration. Cyclophosphamide-induced hyponatraemia was defined as serum sodium concentration <135 mEq/L at 24 hours after the therapy in patients whose basal serum sodium concentrations were normal.
After the low-dose intravenous pulse cyclophosphamide, serum sodium concentration significantly decreased from 139.9 +/- 3.5 to 137.9 +/- 5.1 mEq/L (P < 0.001). Cyclophosphamide-induced hyponatraemia occurred in 15 treatment episodes (13.4%) from 12 patients (14.3%). Patients with hyponatraemia were significantly older than those without hyponatraemia (57.3 +/- 14.7 vs. 40.0 +/- 17.0 years, P < 0.01). Hyponatraemia was associated with male sex on univariate analysis (P < 0.05), but not on multivariate analysis. No factors were found to independently predict the occurrence of cyclophosphamide-induced hyponatraemia when multivariate analysis was performed including parameters age, sex, underlying disease, presence or absence of comorbidities associated with hyponatraemia, presence or absence of concurrent medications associated with hyponatraemia and dose of cyclophosphamide.
Hyponatraemia occurring after low-dose intravenous pulse cyclophosphamide is not rare, especially when hypotonic solutions are adopted for hydration protocol. Thus, the use of hypotonic fluids should be avoided when using cyclophosphamide. Instead, isotonic solutions should be used if a forced diuresis is required.
环磷酰胺是一种烷化剂,传统上被认为能增强血管加压素的肾脏作用。虽然低剂量静脉推注环磷酰胺治疗在恶性和风湿性疾病的治疗中得到广泛应用,但仅有少数关于环磷酰胺引起低钠血症的病例报告。
对 84 例(42 例狼疮肾炎;42 例非霍奇金淋巴瘤;共 112 个治疗期)接受静脉推注环磷酰胺(500-750mg/m²)治疗的患者进行回顾性临床数据分析。在所有患者中,均使用半等渗盐水进行预防性水化。在基础血清钠浓度正常的患者中,将治疗后 24 小时血清钠浓度<135mEq/L 定义为环磷酰胺引起的低钠血症。
低剂量静脉推注环磷酰胺后,血清钠浓度从 139.9±3.5mEq/L显著下降至 137.9±5.1mEq/L(P<0.001)。12 例患者(14.3%)的 15 个治疗期发生环磷酰胺引起的低钠血症。低钠血症患者的年龄明显大于无低钠血症患者(57.3±14.7 岁比 40.0±17.0 岁,P<0.01)。单因素分析显示,低钠血症与男性有关(P<0.05),但多因素分析则不然。多因素分析包括年龄、性别、基础疾病、是否存在与低钠血症相关的合并症、是否存在与低钠血症相关的合并用药以及环磷酰胺剂量等参数时,未发现任何因素能独立预测环磷酰胺引起的低钠血症的发生。
低剂量静脉推注环磷酰胺后发生低钠血症并不罕见,特别是在采用低渗溶液进行水化方案时。因此,使用环磷酰胺时应避免使用低渗液,而需要强力利尿时则应使用等渗液。